The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease.
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/n...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/n...